Retinal Vein Occlusion Market Report 2030 | Retinal Vein Occlusion Market Research Report 2030

 Retinal vein occlusion, one of the most frequently occurring retinal vascular disorders in elderly patients, develops predominantly in individuals over age 65 years. The main risk factors for RVO include age and systemic vascular disorders. It is categorized into central RVO (CRVO) and branch RVO (BRVO) according to the site of blockage in the retinal vein. CRVO is divided further into nonischemic and ischemic types according to the perfusion status based on fluorescein angiography. BRVO consists of major branch RVO (when one of the major branch retinal veins is occluded, usually near, or rarely at, the optic disc) and macular branch RVO (when only one of the macular venules is occluded).

DelveInsight’s ‘Retinal Vein Occlusion—Market Insights, Epidemiology, and Market Forecast–2030’ report delivers an in-depth understanding of the RVO, historical and forecasted epidemiology as well as the RVO    market trends in the United States, EU5(Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Geography Covered

·         The United States

·         EU5 (Germany, France, Italy, Spain, and the United Kingdom)

·         Japan

Study Period: 2017–2030

Retinal Vein Occlusion Disease Understanding and Treatment Algorithm

Retinal Vein Occlusion Overview

Macular edema is the major complication of significant visual loss in patients with CRVO and BRVO, and various treatments have been used to improve macular edema and cause regression of intraocular neovascularization.

The initial examination of a patient with an RVO includes all relevant aspects of the comprehensive adult medical eye evaluation, with particular attention to those aspects related to retinal vascular disease. Several tests are being used for the diagnosis of RVO such as Optical coherence tomography (OCT), and fluorescein angiography (FA). Apart from this, Systemic evaluation is often performed in patients with CRVO and is directed by the patient’s age, coexisting risk factors, and medical history. In RVO, intravitreal steroids and anti-VEGF therapy are used in cases of macular perfusion and macular ischemia, with the laser of use in situations of neovascularization.

Retinal Vein Occlusion Treatment

A person suffers from RVO when one of the veins in the retina becomes blocked. It may lead to varying degrees of vision loss, depending on the severity and location of the blockage. Currently, some of the treatments for retinal vein occlusion include: Intravitreal Injection of Anti-Vascular Endothelial Growth

Factor (VEGF) Drugs, Intravitreal Injection of Corticosteroid Drugs, Focal Laser Therapy, and Pan-Retinal Photocoagulation Therapy.

Intravitreal injections are used to administer medications to treat a variety of retinal conditions. Age-related macular degeneration (AMD), diabetic retinopathy, and RVO are the most common conditions treated with intravitreal anti-VEGF drugs. In addition to this, Intravitreal steroids are also used in diabetic retinopathy, RVO, and uveitis. The anti-VEGF drugs and steroids help reduce fluid leakage associated with these disorders. At present, Anti-VEGF drugs are markedly more effective in the treatment of RVO than any other treatment modality. Among all the available treatment choices, anti-VEGF drugs provide the greatest improvement in VA.

Request for sample pages: https://www.delveinsight.com/sample-request/retinal-vein-occlusion-market

Retinal Vein Occlusion Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Cases of RVO, Diagnosed Prevalent Cases of RVO, Gender-specific Diagnosed Prevalent Cases of RVO, Age-specific Diagnosed Prevalent Cases of RVO, Type-specific Diagnosed Prevalent Cases of RVO, and Treated Cases of RVO in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.

View epidemiological insights of the report: https://www.delveinsight.com/report-store/retinal-vein-occlusion-epidemiology-forecast

Key Findings

This section provides glimpses of the RVO epidemiology in the 7MM.

· In the year 2017, the total prevalent cases of RVO were 2,225,011 cases in the 7MM, which is expected to increase in the forecast period (2020–2030).

· In 2017, the total diagnosed prevalent cases of RVO in the 7MM were 1,947,496

Click here and get access to free sample pages for Retinal Vein Occlusion Epidemiology Insights.

Retinal Vein Occlusion Drug Chapters

This segment of the RVO report encloses the detailed analysis of the mid- and late-stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval, and patent details of each included drug and the latest news and press releases.

View pipeline insights of the report: https://www.delveinsight.com/report-store/retinal-vein-occlusion-pipeline-insight

Retinal Vein Occlusion Emerging Technique

TLC399 (ProDex): Taiwan Liposome Company

TLC399 is the proprietary BioSeizer formulation of dexamethasone sodium phosphate (DSP), intended as an intravitreal, or in-eye, injection for the treatment of macular edema due to retinal vein occlusion. TLC399 in preclinical models has been shown to provide therapeutic levels of DSP in the eye for at least six months after a single administration and have also demonstrated its potential to decrease the thickness of the retina and improve vision. A phase I/II safety trial has demonstrated encouraging signs of efficacy in both the reduction of retinal central subfield thickness and improvements in visual acuity. A larger randomized, double-blind, dose-finding phase II trial is underway. The company is also evaluating opportunities to develop TLC399 in diabetic macular edema in combination with intravitreal anti-VEGF drugs.

GB-102: Graybug Vision

GB-102 is an intravitreal, microparticle depot formulation of the anti-VEGF sunitinib. Sunitinib is a small molecule receptor tyrosine kinase inhibitor that acts as a potent inhibitor of all VEGF pathways, which are known to cause angiogenesis and vascular leakage in the retina, leading to vision decline. The VEGF pathways play an influential role in the development and progression of wet AMD, and there is mechanistic and clinical evidence indicating that a more complete inhibition of these pathways, as offered by sunitinib, could lead to superior patient outcomes compared to current treatments that target only limited VEGF pathways, specifically VEGF-A. The company believes that extending the duration of treatment while expanding the spectrum of neovascular inhibition of all VEGF pathways is differentiated from the current standard of care and may lead to better patient outcomes (Graybug Vision).

More products and detail in the report…

Click here and get access to free sample pages of Retinal Vein Occlusion pipeline insights.

Retinal Vein Occlusion Market Outlook

Retinal vein occlusion (RVO) is a common vascular disorder of the retina and one of the most common causes of vision loss worldwide. Specifically, it is the second most common cause of blindness from retinal vascular disease after diabetic retinopathy.

There’s no medication available that’s specific for retinal artery occlusions. Most people with this condition will have permanent changes to their vision. The main goal of treatment is to stabilize vision by sealing off leaking blood vessels.

Unfortunately, there is no way actually to unblock retinal veins. However, the doctor can treat any health problems that seem to be related to RVO. Vision may come back in some eyes that have had an RVO. About one-third have some improvement, about one-third stay the same and about one-third gradually improve, but it can take a year or more to learn the outcome. In some cases, the blocked vessels will lead to fluid accumulation in the retina, like sponges absorbing water. In others, they may cause the formation of new blood vessels. The current treatment options of RVO intend to minimize the damage, as there is no proven treatment to improve vision loss in the long term. The therapy aims to prevent further visual loss and its complications, such as macular edema, ischemia, or neovascularization.

Some of the treatments for RVO include Intravitreal injection of anti-vascular endothelial growth factor (VEGF) drugs. These drugs target VEGF, which is an important growth factor that causes macular edema. Intravitreal injection of corticosteroid drugs is the type of drug to combat the inflammatory components which lead to edema. Intraocular injections of steroids are another potential treatment for eyes that don’t respond to anti-VEGF drugs.

According to DelveInsight, the RVO market is expected to change in the study period 2017–2030.

Key Findings

This section includes a glimpse of the RVO 7MM market.

· The current market of RVO in the 7MM was USD 2,127.70 million in the year 2017.

· TLC399 (ProDex), AR-1105, and GB-102, are the phase II therapies that are expected to enter the market in the forecast period (2020–2030). All these therapies are going to compete with the current corticosteroids and will be targeting the BRVO and CRVO patient pool.

Market Outlook for Seven Major Markets

This section provides the total Retinal Vein Occlusion market size and market size by therapies in the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan.

Download full report: https://www.delveinsight.com/report-store/retinal-vein-occlusion-market

Download free sample pages: https://www.delveinsight.com/sample-request/retinal-vein-occlusion-market